On April 6, the U.S. Food and Drug Administration held a public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when selecting a treatment.”
On April 4, the Alliance for Aging Research’s Vice President of Public Policy Cynthia Bens will testify before the U.S. Senate Committee on Health, Education, Labor and Pensions about the reauthorization of the Prescription Drug User Fee Act and the Medical Device User Fee Act. You can watch the hearing here.
In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.
On April 7, the Alliance's Vice President of Public Policy Cynthia Bens will participate in a symposium titled "Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target" at the 28th Annual EuroMeeting in Hamburg, Germany.
Nonprofit Leader Dan Perry to Offer Insights at MipTec European Health Care Innovation Conference
Sign up for our email newsletter, Living Longer & Loving It, for the latest information on scientific research on aging and health.
* These fields are required.
Going so soon?
Don’t forget to get your tickets to our Annual Bipartisan Congressional Awards Dinner, Heroes In Health: An Evening To Celebrate Connection, Resilience, And Healthy Aging, on Oct. 2 at the United States Institute of Peace in Washington, D.C.!